ReviewCurrent psychiatry reports2014
Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.
Review in Current psychiatry reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Modeling the Determinants of Subjective Well-Being in Schizophrenia.Schizophrenia bulletin · 2025Trial
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- Pharmacological Intensification Strategies in Highly Refractory Obsessive-Compulsive Disorder: Evidence Synthesis and a Tertiary-Care Case Series.Journal of clinical medicine · 2026Review
- Negative symptomatology and clozapine-induced obsessive-compulsive symptoms: a cross-sectional analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- [Update on obsessive-compulsive and related disorders].Der Nervenarzt · 2025Article
- Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review.BMC psychiatry · 2025Article
- Breaking New Ground With Endoxifen: Augmentation Strategies in OCD Management-A Case Series.Case reports in psychiatry · 2025Article
- Parental mental disorders in patients with comorbid schizophrenia and obsessive-compulsive disorder: a nationwide family-link study.European child & adolescent psychiatry · 2024Article
- Unraveling the Boundaries, Overlaps, and Connections between Schizophrenia and Obsessive-Compulsive Disorder (OCD).Journal of clinical medicine · 2024Review
- Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia.European archives of psychiatry and clinical neuroscience · 2024Article
- Very early onset dementias: Importance of differentiating from schizophrenia spectrum disorders.PLOS mental health · 2024Article
- The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.Biomolecules · 2023Review
- Moving beyond first-line treatment options for OCD.The mental health clinician · 2022Article
- Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.Pharmacopsychiatry · 2021Article
- Classification of comorbidity in obsessive-compulsive disorder: A latent class analysis.Brain and behavior · 2020Article
- The Relationships Between Obsessive-Compulsive Disorder and Psychosis: An Unresolved Issue.Clinical neuropsychiatry · 2020Article
- Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia.Frontiers in psychiatry · 2020Article
- Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature.Current psychiatry reports · 2019Review
- Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder.Indian journal of psychiatry · 2019Review
- Protein-Protein Interaction Analysis of Common Top Genes in Obsessive-Compulsive Disorder (OCD) and Schizophrenia: Towards New Drug Approach Obsessive-Compulsive disorder (OCD) and Schizophrenia Comorbidity Gene Analysis.Iranian journal of pharmaceutical research : IJPR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Second generation antipsychotics (SGAs) have been implicated in the de novo emergence and exacerbation of obsessive-compulsive symptoms (OCS) in patients with schizophrenia. Among SGAs, clozapine, olanzapine, and risperidone are the most prominent agents associated with these sequelae, according to case reports. Comorbid OCS can impede recovery by compromising treatment benefits, medication compliance, and clinical prognoses. Previous reviews of SGA-induced OCS have predominantly focused on descriptive case reports, with limited attention paid toward experimental findings. To address this paucity of data, we sought to review the effects of SGAs on OCS in schizophrenia in the experimental literature, while addressing the role of different treatment (duration, dose, serum levels) and pharmacogenetic factors. Our findings suggest that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28% of clozapine-treated patients experiencing de novo OCS, in addition to 10 to 18% incurring an exacerbation of pre-existing OCS. Clozapine can also yield full threshold obsessive-compulsive disorder (OCD), in some cases. Olanzapine is another high risk drug for secondary OCS which occurs in 11 to 20% of schizophrenic patients receiving olanzapine therapy. At this time, there is insufficient experimental evidence to characterize the effects of other SGAs on OCS. Despite some experimental support for the involvement of longer treatment duration and genetic factors in mediating drug-induced OCS, more research is needed to clearly elucidate these associations. Based on these results, schizophrenic patients should be routinely monitored for OCS throughout the course of SGA treatment, particularly when clozapine or olanzapine is administered.
Indexed as
Identifiers
25256097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.